🇺🇸 FDA
Patent

US 9266813

Stilbenoid compound as inhibitor for squamous carcinoma and hepatoma and uses thereof

granted A61PA61P35/00A61P43/00

Quick answer

US patent 9266813 (Stilbenoid compound as inhibitor for squamous carcinoma and hepatoma and uses thereof) held by China Medical University expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
China Medical University
Grant date
Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61P, A61P35/00, A61P43/00